Mitsubishi UFJ Financial Group Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $21.68 (market cap $252.11B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 24× Vaxcyte Inc. Common Stock's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays a 2.41% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 2 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MUFG | PCVX | |
|---|---|---|
Market Cap | $252.11B | $10.51B |
Volume | 3,452,336 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $24.13 | $73.82 |
52-Week Low | $14.77 | $40.32 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $29.18T | $9.14B |
Dividend Yield | 2.41% | — |
Signals from Pluang's Aura AI — not financial advice
MUFG trades at $22.40, up 0.22% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 exceeding the $0.35 estimate. Fundamentals show robust profitability with a 34.22% net income margin and 12.6% ROE, while valuation ratios like a P/E of 14.99 appear reasonable. Recent news highlights a partnership with SkyDrive for eVTOL feasibility studies and positive analyst momentum coverage.
The outlook is supported by earnings momentum and a 100% buy rating from analysts, but risks include a high debt-to-asset ratio of 5.81 and significant negative cash flow trends. Investor sentiment is optimistic due to strong quarterly results and institutional interest, though technical weakness and macroeconomic sensitivity pose near-term challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →